Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRF | P10586 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11233436 | 0.85 | KMT2A (0.55) | KDM1AMAPTMEN1KMT2ALMNA | |
| SCHEMBL14567837 | 0.81 | L3MBTL1 (0.61) | PTPRFPTPN2PTPN1PTPN11MAPT | |
| SCHEMBL23529671 | 0.80 | PTPRF (0.56) | PTPRFPTPN2PTPN1PTPN11MAPT | |
| SCHEMBL15600303 | 0.80 | KDM1A (0.54) | KDM1AMAPTMEN1KMT2ALMNA | |
| SCHEMBL6483439 | 0.79 | PKM (0.45) | PTPN2PTPN1KDM1AMAPTMEN1 | |
| SCHEMBL15380348 | 0.78 | VCAM1 (0.54) | KDM1AMEN1KMT2AVCAM1SMN1; SMN2 | |
| SCHEMBL28555521 | 0.78 | SMN1; SMN2 (0.59) | KDM1AMAPTMEN1KMT2ALMNA | |
| SCHEMBL9511525 | 0.78 | VCAM1 (0.56) | KDM1AMAPTMEN1KMT2ALMNA | |
| SCHEMBL29936572 | 0.78 | VCAM1 (0.56) | KDM1AMAPTMEN1KMT2ALMNA | |
| SCHEMBL1726825 | 0.78 | KDM1A (0.53) | KDM1AMAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PTPRF 950/4885PTPN2 2115/4885PTPN1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.